Oncology

Latest News

The report suggests a TBS cutoff value of 3 will serve as a meaningful prognostic tool in HCC, but differences in patient populations and imaging techniques may affect the value of that cutoff, the authors noted. | Image credit: Jo Panuwat D - stock.adobe.com

HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA

By Jared Kaltwasser

May 7th 2025

Patients with a high tumor burden score had poorer outcomes following microwave ablation, the investigators found.

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com

Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

By Hayden E. Klein

May 6th 2025

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com

COA 2025: Insight, Innovation, and Independent Strength

By Maggie L. Shaw

May 5th 2025

Community Oncology Reacts to Trump's Drug Pricing Executive Order

By Maggie L. Shaw

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com

5 Things You Should Know About Skin Cancer

By Pearl Steinzor

May 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

January 19th 2015

Results Project Savings for Payers With Novel Oral Anticoagulants

Mary K. Caffrey

January 19th 2015

SPIRIT 2: Dasatinib Superior to Imatinib in Newly Diagnosed CML

Surabhi Dangi-Garimella, PhD

January 19th 2015

CML Updates: Defining MMR and Results of the DASISION Trial

Surabhi Dangi-Garimella, PhD

January 19th 2015

Sessions Report Phase 2 Results of Pomalidomide Combinations

Mary K. Caffrey

January 19th 2015

Promising Results for Elotuzumab Presented in Session on Multiple Myeloma

Mary K. Caffrey

January 19th 2015

Early Treatment, Monoclonal Antibodies Discussed in Multiple Myeloma

Mary K. Caffrey

January 19th 2015

ASH Presents Second Round of Tests, Treatments to Question Under Choosing Wisely Initiative

Mary K. Caffrey

January 19th 2015

Care Plans to Reduce Healthcare Utilization in Sickle Cell Disease

Surabhi Dangi-Garimella, PhD

January 19th 2015

Poster Presentations Cover Therapeutic Options in CML

Surabhi Dangi-Garimella, PhD

January 19th 2015

Pharmacists Ease Cancer Patients' Financial Burdens

A new study on the effects of cancer patients' financial burdens suggests that pharmacists can play a role in easing or preventing some of their stress.

January 19th 2015

Healthcare Costs in Need of Solutions: Experts at ASH Agree

Surabhi Dangi-Garimella, PhD

January 19th 2015

Session on Survivorship Outlines Surveillance Strategies in Non-Hodgkin Lymphoma

Mary K. Caffrey

January 19th 2015

Ibrutinib Demonstrates Significant Responses for Patients With Hard-to-Treat CLL/SLL, Phase 2 Data Show

Mary K. Caffrey

January 19th 2015

Study Suggests Method of Reducing Blood Clots Without Risking Bleeding

Mary K. Caffrey

January 16th 2015

UCLA Study Unveils Mechanism of Melanoma Drug Resistance

Researchers have uncovered how melanoma becomes resistant to a promising new drug combo therapy utilizing BRAF+MEK inhibitors in patients after an initial period of tumor shrinkage.

January 16th 2015

Study Indicates Improved Survival in CRC Despite Lower Surgery Rates

The research, published in JAMA Surgery, analyzed data collected from NCI's SEER database, between 1988 till 2010, on stage 4 CRC patients who had surgery or not for primary tumor resection. Survival data on these patients was then analyzed and associated with their surgical status.

January 16th 2015

Predictive Value of Diagnostic Tests

January 16th 2015

Development and Use of Diagnostic Testing

January 16th 2015

Predictive Value of Diagnostic Testing

January 16th 2015

Clinical Utility of Genomic Testing

January 16th 2015

Use of Molecular Tests That Assess Risk of Recurrence

January 15th 2015

Spanish Team Identifies Gene Variant Responsible for Susceptibility to Peripheral Neuropathy

The authors of the research say that this information could be especially valuable for the Spanish population: "Even though these variants are rare or not frequent in the population, their frequency is greater in Spain than in other countries."

January 15th 2015

Metabolic Syndrome A Significant Risk Factor in Endometrial Cancer, Study Finds

Overall, metabolic syndrome was associated with a 39 percent to 103 percent increased risk of endometrial cancer in women 65 and older, according to the study.

January 15th 2015

Patients With Metastatic Colorectal Cancer Having Less Surgery, Yet Survival Rates Improving

With the dawn of the modern era of new chemotherapeutic and biologic agents available for managing their disease, patients with metastatic colorectal cancer are undergoing less surgery for the removal of their primary tumors.

January 15th 2015

Can We Follow the European Model to Curb Drug Costs, Asks Dr Peter Bach

In an Ope-Ed in The New York Times , Peter Bach, MD, from the Memorial Sloan Kettering Cancer Center, questions the rising drug prices and contemplates solutions.

January 14th 2015

ASCO Staff Raising Healthcare Issues with Federal and State Legislators

Members of the ASCO Government Relations Committee are busy meeting Members of Congress as well as State Affiliates to address a number of healthcare issue early in the year.

January 14th 2015

Cancer Treatments the Next Big Area for Cost Saving Opportunities

Laura Joszt, MA

Involving the pharmacy benefits manager earlier in the decision-making process could lead to cost savings on cancer treatments, Express Scripts Chief Executive Officer George Paz said at the J.P. Morgan Healthcare Conference in San Francisco, California.

January 14th 2015

Diagnostic Testing Guidelines for Lung Cancer to Be Revised

In addition to recommendations on alternate techniques, the revised guideline, being jointly developed by CAP, IASLC, and AMP, will also include testing for emerging biomarkers in lung cancer.

January 14th 2015

Express Scripts Wants Early Discussions to Help Lower Treatment Costs

After their decision to include Abbvie's triple combination for hepatitis C on their formulary, over Gilead's more expensive regimens, Express Scripts indicated at the J. P. Morgan Healthcare Conference that they'll continue the stance of choosing treatments that are equally effective but save costs, especially in cancer.

January 13th 2015

"Choose Wisely" in Rectal Cancer a Retrospective Study Indicates

The retrospective analysis of 145 patients with stage 2-3 rectal cancer found that the "wait and watch" approach, instead of surgery, in patients treated with chemotherapy might work just as well when measuring survival as an outcome.

...

141 142 143 144 145 146 147 148 149

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions